<DOC>
	<DOCNO>NCT02188355</DOCNO>
	<brief_summary>The e-Ultimaster validate safety efficacy Ultimaster DES system unselected patient represent everyday clinical practice . Also study assess impact non-compliance dual antiplatelet therapy , one month stent implementation ( frequently observe every day clinical practice ) , stent thrombosis .</brief_summary>
	<brief_title>Prospective , Single-arm , Multi Centre Observations Ultimaster Des Registry</brief_title>
	<detailed_description>All consecutive patient suitable treatment DES accord hospital routine practice centre across world agree participate e-ULTIMASTER registry treat Ultimaster DES . Secondary objective Evaluation worldwide utilization DES , Detection rare event representative patient population , identification predictor major advers event , assessment radial access site utilization impact bleed vascular complication , assessment procedural particularity patient pathology wide geographic area , assessment duration type DAPT , assesment performace Ultimaster DES patient lesion subset , assessment possible benefit biodegradable polymer lager complex patiets/lesions subset assessment sirolimus efficacy different race . Data collect e-CRF online monitoring do . Audits allow sponsor qualify designees .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>18 year older eligible percutaneous coronary intervention use DES ( RVD match available Ultimaster DES size ) inform nature study agreess provisions provide write informed consent approve Institutional Review Board / Ethics committee respective clinical site , wherever requirement exists . follow instruction use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ultimaster</keyword>
	<keyword>registry</keyword>
	<keyword>DES</keyword>
	<keyword>DAPT</keyword>
</DOC>